in the incidence of scabies and/or supposed causes may result in a distorted picture (publication bias), since studies in which no change is observed are less likely to be published than those that indicate an increase in the incidence of a disease. We have tried to take this bias into account in this review.
Scabies has been present in Germany for centuries. However, according to data collected by the Kassenärztliche Vereinigung Nordrhein (North Rhine Association of Statutory Health Insurance Physicians) from 2014 to 2016, the number of patients who received treatment for scabies in the district of North Rhine increased by around 200 % (from 6,579 to 19,560) [ 2 ] . Similarly, there was also an increase in the diagnosis of scabies (ICD10 Code B86) in inpatient cases (2010: 755 cases, 2016: 3855 cases, but the number was less than in 1994 with 4511 diagnoses [ICD-9 Code 133]) [ 3 ] . However, regional differences were noted: for example, in North Rhine-Westphalia, the incidence rose from 5 to 10 diagnoses per 100,000 inhabitants per year, while in some federal states it fell slightly.
An internal survey by the Barmer health insurance company showed that the number of prescriptions of permethrin, ivermectin and benzyl benzoate increased by 60 % in 2017 compared to 2016 (from 38,127 to 61,255). This increase varied between regions: 129 % in Schleswig-Holstein, 98 % in Bremen, 89 % in Rhineland-Palatinate and 35 % in Berlin [ 4 ] .
Sales by German pharmacies showed a fourfold increase between 2012 and 2017 for the group permethrin, allethrin, benzyl benzoate and ivermectin (from 329,000 to 1,247,000 packages delivered per calendar year, source: "Apothekeneinkaufsdaten der öffentlichen Apotheken in Deutschland [Pharmacy sales data for public pharmacies in Germany]", INSIGHT Health, 5/2018) . In this context it should be noted that sometimes two or more scabicides are prescribed per patient and, in our opinion, contact persons are treated more frequently today than in the past.
In 2016, the Robert Koch Institute analyzed scabies cases that were reported by 126 of the 378 public health institutions in Germany for 2015 and 2016. Two-thirds of the institutions reported an increase, about 20 % a decrease and no difference was noted in the remaining public health offi ces (A.A., unpublished data).
In Germany, there is no obligation to register cases of scabies in accordance with the Infection Protection Act ((Infektionsschutzgesetz) IfSG). Only employees responsible for community facilities are required to report infestations for supervised or caregiving persons in an institution if they "have scabies or are suspected of having scabies". It is only since 2017 that this obligation also applies to care institutions, prisons, homeless shelters, accommodations of asylum seekers and refugees as well as other large accommodation facilities [ 5 ] . It is therefore conceivable that the increasing number of reports to the responsible institutions since 2017 may be due to the broader reporting obligations.
Overall, awareness of scabies has increased in recent years, so that healthcare personnel and people in general are more aware of the diagnoses, whereas in previous years scabies was probably overlooked in some cases. If diagnoses are made exclusively with clinical observation, but without microscopic detection of mites, an increase in false-positive diagnoses can be expected. With the known low specifi city of the clinical diagnosis and a low overall prevalence of scabies (< 1 %), both at the population level and the outpatient level, the positive predictive value of the clinical diagnosis is low and the proportion of false-positive diagnoses is high.
So the above-mentioned data indicate an increase in the incidence of scabies, but do not quantify it, and the proportion of unconfi rmed diagnoses is unknown. Comparison of frequencies is therefore problematic.
Frequency of lege artis diagnosed scabies in inpatient setting
In order to obtain reliable data, one of the authors (A.K.) obtained retrospective numbers of inpatient diagnoses of scabies (confi rmed by dermatoscopy or microscopy of skin scrapings) at the Dermatology Department in Oberhausen (Germany) between 2012 and 2017. Oberhausen is located in a federal state with an assumed increase in scabies (see above). All patients had been treated unsuccessfully as outpatients at least once before they were admitted for inpatient treatment. The numbers show that there has been a steady increase from 60 in 2012 to 415 patients in 2017 (in absolute terms); when looking at percentages of diagnoses of all admitted inpatients it rose from 5.1 % to 13.3 % per year (Table 1 ) . In the Department of Dermatology at Ludwigshafen Hospital -also in a federal state with increased prescription fi gures for scabicides -the diagnosis of scabies has been confi rmed for years either by microscopy or dermoscopy, so that the author C.L. was able to retrospectively analyze the number of cases for this article in the same way: between 2012 and 2016, between one and nine patients per year were admitted for inpatient treatment of scabies, while in 2017 the number rose to 56. These observations indicate that in some hospitals the number of inpatients with confi rmed diagnoses of scabies is increasing, but they do not yet prove a general increase of inpatient cases in the respective region, let alone in Germany. Likewise, these data suggest (but do not prove) an increased number of outpatient cases that appear to be resistant to treatment.
Possible reasons for an increase in scabies -risk groups
An increase in scabies cases in Germany could probably be explained by an increase of risk groups or in the occurrence of factors that are known to favor an increased prevalence. These risk factors are common in southern countries where scabies is highly prevalent in all age groups (up to 50 % in children and up to 10 % in the total population) [ 6 ] and encompass poverty, poor sanitation, high population density and living close together in small spaces [ 7 ] .
Population registries from the UK and Denmark enable epidemiological studies [ 7, 8 ] and comparisons with times in the past when widespread risk factors facilitated the dissemination of scabies (e.g. Edinburgh in the early 20th century [ 9 ] ). These studies have enabled identifi cation of groups with increased prevalence or increased risk of scabies. In the United Kingdom, a higher rate of infestation of women and children in the age group of 10 to 19 years was documented for the period from 1997-2005. In Denmark, a higher rate of infestation was noted for the period from 1900-1975 in infants, children and adolescents. Both surveys recorded increases during the winter [ 7, 8 ] .
For Germany, there are no epidemiological statistics that allow a comparison of the current situation with earlier periods. Therefore, we looked for indirect evidence of groups in which prevalence might have increased.
Children
Children are an underestimated source of infection with scabies because i) its prevalence tends to be higher in children than in adolescents and adults, ii) children are more likely to develop a type of scabies with more numerous mites [10] [11] [12] , and iii) they tend to receive inadequate management, because the face and scalp are often spared from topical treatment, despite of and contrary to the recommendations in guidelines [ 10, 13 ] . If the absolute number of children with scabies has increased in recent years, this could have led to an increase in other age groups, especially since diagnosis of scabies is not always promptly made in children. In our experience, children are also a potential source of re-infestation because their treatment does not always involve the whole body (see below), while close body contacts are soon resumed.
Immunosuppressed and immobile elderly patients
As a result of increased life expectancy, the number of people with multiple disabilities, long-term care and immunosuppression increases, with an associated susceptibility to crusted scabies. This increases the risk of outbreaks in care facilities and of transmission outside these facilities. However, such an increase is not proven, because the confi rmation or quantifi cation of such effects has only been possible in Germany since the revision of the Infection Protection Act (IfSG) in 2017 with broader reporting obligations of care facilities.
Risk groups for sexually transmitted diseases
Intimate contacts are a common route of transmission [ 14 ] , and promiscuity is a risk factor for scabies [ 8, 15 ] . Adolescents and young adults in Western Europe are at increased risk of becoming infected with scabies [ 7 ] . An increase of scabies in this group might well occur in the wake of the generally increasing numbers of sexually transmitted diseases in recent years [ 16 ] .
Migrants and refugees
An increase in scabies due to migration has been documented in Europe during and after the two World Wars [ 9, 17 ] . However, the social and hygienic conditions of those times are not comparable to the current situation which includes migration of refugees from war or battle zones. Many refugees from the Middle East and Africa come from countries with a high prevalence of scabies [ 7 ] . Migrants (often families with numerous children) live -at least temporarily -in crowded facilities with a high density of occupants. Therefore, the prevalence of scabies among refugees is probably much higher than in the German population [18] [19] [20] . But refugees usually have no crusted scabies and no skin contact that would be suffi cient for transmission to the native population during their stay in collective facilities. These refugees therefore are unlikely to cause major outbreaks outside these facilities.
However, outbreaks of scabies [18] [19] [20] and other notifi able infectious diseases do occur inside migrant and refugee accommodations. While a total of 11 outbreaks were registered in 2004, there were 331 in 2014. They included chicken pox (30 %), measles (20 %) and in third place scabies (19 %); outbreaks of rotavirus gastroenteritis (8 %) and tuberculosis (3 %) were less common [ 18 ] . Still, spread of a pathogen to the general population was only described for measles [ 18 ] . According to the Robert Koch Institute, migrants and refugees do not represent a generally increased risk of infection for the general population [ 19 ] . However, no epidemiological statistics are available to confi rm this statement. It cannot be ruled out that some patients had unrecognized or inadequately treated scabies before moving out of refugee facilities, and that scabies mites might have been subsequently transmitted to other individuals in single cases.
Migration of workers in the low-wage or nursing sector
An increasing number of workers come to Germany from other parts of the European Union and from other economic areas. They usually come from poorer regions and mainly work in the low-wage sector, but also in the primary care sector or nursing facilities for the elderly (statistics from the German Federal Employment Agency) [ 21, 22 ] . These employees are exposed to a higher risk of infection in nursing and care facilities [ 23 ] , and they also come from regions with a higher prevalence of scabies [ 7 ] . Furthermore, they often are accommodated in confi ned spaces and have to change jobs and work places more often (German Federal Statistical Offi ce) [ 24, 25 ] . There is a lack of relevant studies, whether these circumstances would contribute to dissemination of scabies in Germany.
In summary, it can be assumed from the available data that (numerical) changes in some or all risk groups may be responsible for the reported increase in scabies in Germany. In order to identify causal relationships, epidemiological studies are needed.
Resistant mites
The presumed increase in the frequency of scabies is accompanied by observations (especially in the outpatient area) which suggest that even repetitive treatment with permethrin does not cure scabies.
According to an internal survey at the Department of Dermatology in Münster, intact mites were microscopically confi rmed in ten patients from May 2017 to April 2018, despite prior repeated treatments with permethrin: two treatments in two patients, three in two patients, four in four patients and fi ve treatments in one patient. Compliance and adherence seemed to be good in these patients. In two cases, however, it could not be confi rmed whether all contact persons were also treated according to the guidelines. Similar observations have been made at the Departments of Dermatology in Oberhausen, in Ludwigshafen and at the University Hospital in Würzburg.
The effi cacy of permethrin has been proven by numerous clinical studies, although the quality of those studies was not uniformly high (Cochrane and meta-analysis data from 2018 [ 26, 27 ] ). There are three possible explanations for a failure to respond to permethrin treatment: 1 Incorrect use of permethrin. 2 Reinfestation due to incomplete management of surroundings, such as contact persons and items (clothing, bedding, towels etc.).
3
Insensitivity/resistance of scabies mites to permethrin.
Re 1: Incorrect use of permethrin includes, for example, inadequate exposure time to permethrin, failure to shorten fi ngernails (which may harbor subungual mites after scratching), inadequate (pre) treatment of hyperkeratosis/ pronounced scaling, or failure to apply permethrin to heads in toddlers (or adults with rashes on their heads) [ 14 ] . In a retrospective study, failure to respond to treatment was related to a lack of repeated treatment or failure to reapply permethrin to hands after washing them [ 28 ] (as a repeated application of permethrin is not generally indicated [ 26 ] , the reason for failure may also be explained by errors during initial treatment).
Compliance with topical therapies is generally poor, also other dermatoses [ 29, 30 ] , a fact that should be made aware repeatedly. Even though permethrin is a one-time treatment, it therefore can be assumed that correct application is often not carried out properly due to compliance issues. It is possible that scabicides that -unlike permethrin -must be applied for several days (e.g. crotamiton, benzyl benzoate) are more likely to "forgive" errors in application than permethrin, which is only applied once.
Re 2: Errors in the management of surroundings can be manifold. Re-infestation of unrecognized or insuffi ciently treated contacts is common [ 28 ] . In our experience, children who have been infected by other children with (yet) undiagnosed scabies are overlooked as a possible source of infection [ 8, 11, 17 ] . Often, some contacts receive no treatment, even in families. Occasionally, secret sexual affairs or unrecognized crusted scabies (e.g. grandmother misdiagnosed with psoriasis), are the cause of (re-) infestation.
Since infants often have scabies with numerous mites, transmission via shared blankets, sleeping bags etc. may be more common than in adults [ 31 ] .
In our experience, it is often diffi cult for affected families and elderly people to properly understand and carry out all measures and to remember all contact persons, especially if their native language is different from that of the physician. In case of repeated infestations, it may be helpful to pay more attention to individual circumstances. Home visits or involvement of (public) health offi ces might also be indicated.
Re 3: Several colleagues have not found evidence of any of the above-mentioned errors in patients with recurrent scabies despite treatment [ 1 ] . Although we (A.K., M.N., H.H., C.S. and C.L.) were often able to treat such cases successfully once they were admitted to the ward as inpatients, we have the impression that patients do not respond to treatment with permethrin as quickly today as they used to some years ago.
The pharmacokinetics of permethrin in the skin is unknown (data are only available for systemic absorption in adults). Since the number of mites in children is -at least temporarily -higher than in adults [ 10 ] , knowledge of the pharmacokinetics of permethrin in the skin of children is essential. As long as these data are missing, we recommend a repeat treatment in children -but not on the following day because of reported toxicity [ 32 ] . A disadvantage of the available permethrin ointment is its sometimes difficult application and regular distribution on the whole skin surface due to its galenic qualities, especially on adult males with dense body hair (in these cases even shaving of body hair is sometimes recommended).
An Australian team has described prolonged survival of Sarcoptes scabiei var. hominis after contact with permethrin, which was associated with higher transcription of glutathione-S-transferases [ 33 ] . It has been shown with Sarcoptes scabiei var. suis (permethrin-naive mites) and Sarcoptes scabiei var. canis (not (!) var. hominis ) (permethrin-resistant mites due to long-term use of permethrin [ 34 ] ), that the combined activity of esterases, glutathione-S-transferases, cytochrome P450 and monooxygenase may reduce sensitivity to permethrin and other scabicides [ 35 ] . Based on (non-standardized) resistance testing, the required exposure time of permethrin to mites has increased in Australian endemic areas over the years, but without development of resistant mites [ 36 ] . In Sarcoptes scabiei var. canis , a mutation in the gene for the voltage-gated sodium channel was found (target structure of permethrin in lice and other arthropods), and the so-called knockdown resistance (kdr) mutation was detected in mites that did not die immediately after permethrin exposure [ 34 ] . This kdr mutation has previously been detected in lice. However, as with lice, all scabies mites ultimately died within 24 hours of permethrin exposure [ 34 ] . The relevance of the kdr mutation is there fore questionable for sarcoptic mites and lice, that is for sessile ectoparasites with prolonged exposure to permethrin, whereas the kdr mutation appears to be suffi cient for resistance in non-sessile mosquitoes or other arthropods with only a short exposure to permethrin. However, this mutation has not yet been found in Sarcoptes scabiei var. hominis , nor have other mutations associated with resistance in other arthropods [ 37 ] .
Thus, several mechanisms may theoretically lead to resistance to permethrin [ 38 ] , but have not yet been proven. The urgent question as to whether there are resistant scabies mites in Germany may be answered or at least appproached by sequencing the genome of mites that are collected from patients with documented failure to respond to permethrin despite its correct application according to the guideline. Since there are no established resistance tests for mites, we are currently trying to obtain indirect evidence of possible resistance by detecting motile mites after treatment with permethrin. The author C.L. has observed that in some cases, mites were still motile 12 h after treatment with permethrin, but became immobile after 36-48 h.
These observations are diffi cult to interpret, since it is not known how permethrin infl uences the mobility of scabies mites, and whether mobile mites may leave the host after treatment with permethrin. However, a precautionary measure would be to have patients avoid prolonged body contact for at least 36 hours after initiation of permethrin treatment.
For scabies mites, there is more (although rare) evidence of resistance to ivermectin than to permethrin [38] [39] [40] . Possible causes include genetic alterations of the target structure, the glutamate-directed chloride channel [ 40, 41 ] , or a P-glycoprotein membrane transport protein; the latter has been described in ivermectin-resistant nematodes [ 42 ] , where it leads to outward transfer (effl ux pumps).
Application errors are also possible with ivermectin. Since the effect of food intake on absorption is not well known, patients should refrain from food intake for at least two hours before and after taking ivermectin. As ivermectin accumulates in the stratum corneum, it is recommended that patients do not scrub the skin for a week after ingestion [ 14 ] .
According to current data, it is very unlikely that scabies mites are resistant to both permethrin and ivermectin. Therefore, cases where both therapies are ineffective are probably due to treatment errors.
Faster infestation by mites?
There is no basis for the occasional assumption that mites are now transferred faster and more easily between human beings than before [ 1 ] . More rapid transmission is seen in crusted scabies because mites are more numerous on the surface of the skin than within the epidermis.
Cyclic changes in incidence?
For both scabies and pediculosis, cyclic changes in prevalence have been postulated at a global or continental level (partially summarized in [ 8 ] ). However, the epidemiological data are not suffi cient to support such assumptions, partly because historical periods and populations cannot be meaningfully compared (due, for example, to the special circumstances after the two World Wars). It is noteworthy that during an increase of scabies in the 1960s in England [ 17 ] , similar causes were discussed in England [ 43 ] to those now discussed in Germany. There is no evidence for a herd immunity for scabies, which has been assumed to decrease during a period of declining incidence [ 43 ] .
Conclusion and recommendations
Many signs suggest an increased incidence of scabies in Germany, but there are no exactly quantifi ed data on age-specifi c or regional incidences with confi rmed diagnosis.
Furthermore, there are no reliable data that would explain possible reasons for an increase. None of the causes mentioned above would explain alone the recent increase in scabies, but it is conceivable that regional increases have taken place due in part to migratory movements (workers from economically poorer countries, immigrants from the Middle East and Africa seeking protection) as well as transmission due to an increase in sexually transmitted diseases among adolescents and young adults. It is also possible that undetected infections among infants and non-treated contact persons are a cause, for persistence or re-infestation or that inadequate therapy and lack of adherence/compliance have created the impression of emerging resistance.
According to recent meta-analyses, treatment with permethrin is still effective [ 26 ] . Although permethrin sometimes seems to be less successful than in previous years, we believe that this is unlikely to be due to a widespread resistance of mites to permethrin or ivermectin, whereas we cannot rule out the possibility of reduced sensitivity. Prospective studies with a complete genome analysis of mites (before and after therapy) are needed for clarifi cation.
In conclusion, all measures for the diagnosis and treatment of scabies should be complied with as outlined in the current guidelines [ 14 ] . In addition, the following suggestions should be taken into account:
If persistent scabies is suspected despite correct and credible treatment, the diagnosis should be confi rmed by means of microscopy or dermoscopy. Although a single treatment may be suffi cient for many patients [ 26 ] , we recommend a repeat treatment with permethrin or ivermectin after 7-14 days, with regard to the severity of the infestation, the immune status, and the compliance and adherence of the patient or family [ 26, 27 ] . The timing results from the life cycle of the mites of 10-17 days. Repeat treatment is generally recommended by the European guideline for all patients [ 44 ] and by the German Guideline under certain conditions (for example, to prevent possible application errors). The exposure time of permethrin on the skin should be extended to 12 hours , and intensive body contacts should be avoided for up to 36 hours after therapy. This recommendation is based on the observed mobility of mites for up to 36 hours (but not more than 48 hours) after treatment with permethrin. If good compliance does not appear to be guaranteed, we recommend ivermectin over permethrin, as pointed out in the guideline [ 14 ] . [ 14 ] ).
Patients should be re-examined for new signs of scabies 4-5 days (at the latest 14 days) after successful treatment, and again after 4-6 weeks. When fi rst-line treatment is not possible or effective, further treatment options include crotamiton (10 %) and benzyl benzoate (10 % emulsion for children over the age of 2 with intact skin barrier, and 25 % for patients over 12 years of age).
-Crotamiton: there are few (qualitatively mediocre) studies; they show an effi cacy similar to that of permethrin [ 1, 14, 27 ] . Crotamiton must be applied on 3-5 consecutive days. -Benzyl benzoate: no defi nite recommendation can be made for benzyl benzoate based on available data [ 27 ] . It must be applied on three consecutive days and washed off on the 4 th day. Some dermatologists have the impression that it is effective in patients who still had signs of active scabies after permethrin treatment. Treatment options that are applied on several consecutive days may be less susceptible to errors in application than permethrin.
-Ivermectin: topical ivermectin (1 %) is effective [ 26 ] , but is not approved in Germany for treatment of scabies. If scabies mites are detected after repeated outpatient treatment and denial of possible treatment errors, we recommend inpatient treatment (inpatient care in addition is usually justifi ed by eczematization or impetiginization). Inpatient treatment has two main advantages: fi rstly, permethrin can be applied in a controlled and correct manner, and secondly, all remaining extracutaneous mites in the household die within those 24-36 hours while patients are treated at the clinic. In our experience, if patients undergo treatment precisely according to the guideline as inpatients, they are cured in most cases. However, re-infestation after discharge cannot be prevented. Combination therapies with various scabicides and daily recurring treatment cycles should be avoided with scabies in immunocompetent persons. Although in the current situation, permethrin and oral ivermectin are sometimes prescribed simultaneously, we do not recommend routine combination of both drugs, because (a) there is no evidence for a better outcome, (b) no information is available about interactions and toxicity, especially after multiple pretreatment cycles with permethrin, and (c) there are known mechanisms of resistance to ivermectin. The impression that a combination of ivermectin and permethrin is more effective than therapy with permethrin alone could be partly due to the fact that simultaneous use of ivermectin compensates for incorrect application of permethrin. If treatment of crusted scabies has failed despite being carried out according to the guidelines [ 14 ] , the dose of ivermectin may either be increased [ 14, 46 ] , or recommendations of the CDC [ 47 ] and European guidelines (expert opinions) may be followed: combination therapy with permethrin daily for seven days (not in infants! [ 32 ] ), then twice weekly until resolution of symptoms and additionally oral ivermectin (200 µ g/kg) on days 1, 2, and 8; if mites are still detected microscopically, repeat treatment on days 9 and 15; in severe cases also on days 22 and 29. At this point, however, we would recommend to critically once again evaluate the patient's compliance and adherence. There are no studies on the treatment of crusted scabies , although there is a case report on successful treatment of crusted scabies with multiple dosages of ivermectin [ 48 ] . Repeated treatment with permethrin did not increase the effectiveness [ 26 ] and may lead to intoxication in toddlers [ 32 ] as opposed to adults [ 49 ] .
Diagnosis of scabies
In general:
Dermatoscopic criteria: detection of (a) brownish triangular contour (kite sign, corresponding to the head and breastplate of the mite) in conjunction with (b) the air-filled intracorneal burrow system (resembling the wake of a ship). Microscopic criteria : detection of mites, eggs, or scybala in skin scrapings [ 8 ] . Microscopic detection of mites, eggs, or scybala may be achieved using skin scrapings from the end of the burrows (but not from the eczematous lesions). It is easiest to look on the palms of the hands and soles of the feet for fresh (not inflamed, non-reddened) burrows; the mite-containing ducts are difficult to see because of the slight redness. In families, mites are easiest to find in infants or toddlers, since they are usually more seriously infested.
To do this, the burrow must be opened with a fine needle, lancet, or a fine scalpel at the blind end (where a small papule may be seen), or removed tangentially [ 50 ] . The content is placed on a slide and examined with a microscope (under a coverslip) at low magnification (eyepiece x 10, objective x 10). Another option is to scrape over the burrows with an oiled scalpel blade to which the skin scrapings then stick.
In children, a 4 mm ring curette instead of a (frequently intimidating) scalpel has been proposed. At a 30° angle, it is carefully moved over the papule, which has been dabbed with oil beforehand [ 51 ] . Alternatively, a curette may be used. The scrapings obtained are then placed on an oiled slide with the wooden end of a cotton swab. The typical burrow structures are sometimes easier to visualize without the use of oil. The sensitivity of diagnosis based on skin scrapings is low [ 52 ] .
In crusted scabies, microscopic mite detection is possible with examination of single skin scales; typical burrows/tunnels are frequently missing. Adhesive tape test : For this test, transparent (and strong) adhesive tape is cut to the size of a microscopic slide, firmly pressed onto suspicious burrows, rapidly pulled off, and subsequently attached to the slide (for example, the authors who described this method used "Tartan TM transparent packaging tape" [ 53 ] ). The adhesive tape test is an efficient and timesaving method for outbreaks in nursing homes and mass accommodation facilities. This procedure is contraindicated in patients with fragile skin (dermatoporosis, bullous disease). In pretreated patients, the eggs are still visible (often like a string of pearls), although the mites are dead. On pigmented skin, the kite sign is hardly discernible or not at all [ 52, 54 ] . The sensitivity of dermoscopy depends on the experience of the examiner [ 52 ] .
PCR from tissue samples, especially paraffin embedded tissue, is not a suitable diagnostic tool [ 55 ] .
